NCT00176423View on ClinicalTrials.gov

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

galantamine

see arm/group description

Trial Locations (1)

21228

Maryland Psychiatric Research Center, Baltimore

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

collaborator

Ortho-McNeil Neurologics, Inc.

INDUSTRY

lead

University of Maryland, Baltimore

OTHER

NCT00176423 - Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia | Biotech Hunter | Biotech Hunter